Obesity remains the most important risk factor for the incidence and progression of
osteoarthritis (OA). The leading cause of OA was believed to be overloading the joints due to …

Abstract “Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term
suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation …

Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP)
and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 …

The incretin system is an essential metabolic axis that regulates postprandial metabolism.
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic …

The two β-arrestins, β-arrestin-1 and-2 (systematic names: arrestin-2 and-3, respectively),
are multifunctional intracellular proteins that regulate the activity of a very large number of …

Obesity is the most extended metabolic alteration worldwide increasing the risk for the
development of cardiometabolic alterations such as type 2 diabetes, hypertension, and …

The prevalence of obesity and associated chronic diseases continues to increase
worldwide, negatively impacting on societies and economies. Whereas the association …

Body fat distribution is a heritable risk factor for cardiovascular and metabolic disease. In
humans, rare Inhibin beta E (INHBE, activin E) loss-of-function variants are associated with a …

Obesity-prone (OP) individuals have a significant predisposition to obesity and diabetes.
Previously, we have found that OP individuals, despite being normal in weight and BMI …

Abstract Purpose of Review To discuss evidence supporting the use of glucagon-like
peptide 1 receptor agonists (GLP-1RA) to treat obesity and their role as a cardioprotective …